Global CMC, Lifecycle & Regulatory Data Strategy

Build one technical truth that can survive multiple regions and the product lifecycle.

XGene helps teams align global CMC strategy, lifecycle change logic, dossier content and regulatory data so regional submissions do not drift into competing versions of the product and manufacturing story.

When this service is the right fit

• Regional dossiers have diverged after years of local variations and operational changes.
• A global change needs one technical assessment but different regional regulatory pathways.
• Registered commitments are difficult to reconcile with current manufacturing and analytical practice.
• CMC data is being recreated across documents instead of governed as reusable product information.
• EU IDMP/SPOR readiness and broader regulatory-data initiatives require better master-data ownership and data quality.
• Regulatory, CMC and operations teams do not share one lifecycle evidence model.

What XGene does

• Map the global registered-state and technical-current-state for priority CMC elements.
• Assess change impact, regional dependencies and evidence needed for lifecycle decisions.
• Reconcile dossier, manufacturing, specification, analytical and master-data differences.
• Define governance for reusable CMC content and structured product/regulatory data.
• Assess EU IDMP/SPOR readiness and other relevant data obligations/directions without overstating implementation status.
• Create a lifecycle architecture for future changes, submissions and data maintenance.

What the engagement produces

• Global CMC registered-state / current-state map
• Lifecycle change-impact and regional dependency matrix
• Dossier harmonization gap register
• Regulatory-data ownership and quality model
• IDMP/SPOR readiness assessment where applicable
• Global CMC lifecycle governance roadmap

Productized starting point — Global CMC / IDMP Readiness Review

The Global CMC / IDMP Readiness Review is the recommended first engagement when the organization needs an independent, evidence-based view before committing to a larger remediation, authoring, transformation or execution program. It is designed to identify the decision-critical gaps, clarify scope and produce a prioritized path forward without forcing the client into an oversized engagement at the outset.

How XGene works

1. Define the global product and lifecycle decision.

2. Map registered content, current evidence and master data.

3. Diagnose divergence, ownership and regional-dependency risks.

4. Build harmonized lifecycle/data governance architecture.

5. Stress-test future changes for reuse, traceability and regional consistency.

Senior practitioners aligned to this work

• Khaled Aamer, PhD
• a senior XGene biologics CMC / MS&T practitioner

Experience brought to XGene

The following examples demonstrate relevant practitioner experience. They are not presented as XGene-delivered client outcomes unless explicitly stated otherwise.

• Global CMC authorship/review across IND, NDA, ANDA, BLA and DMF programs plus structured-content/FHIR-HL7 modernization in prior-role and consulting experience (Khaled Aamer).
• Prior-role authorship/review includes IND, IMPD, BLA/sBLA and MAA content with biologics lifecycle and manufacturing-support experience (a senior XGene biologics CMC / MS&T practitioner).

Engagement boundary

XGene does not present future data architecture as a substitute for current regulatory requirements. The objective is to make current obligations easier to maintain while reducing future fragmentation.